bookmark

Pregabalin and gabapentin: what impact will reclassification have on doctors and patients? | The BMJ


Description

From 1 April 2019 pregabalin and gabapentin will be reclassified as class C controlled substances in the UK. The change, announced in October 2018, is expected to prompt a decline in the use of the drugs as prescribing, dispensing, and collecting them becomes more onerous for doctors, pharmacists, and patients. To read the full article, log in using your NHS OpenAthens details.

Preview

Tags

Users

  • @sssftlibrary

Comments and Reviews